Company Filing History:
Years Active: 2018-2020
Title: Linnette Capo - Innovator in Antibody Drug Conjugates
Introduction
Linnette Capo is a notable inventor in the field of biotechnology, particularly known for her work on antibody drug conjugates (ADCs). Her innovative research focuses on developing therapeutic compositions for cancer treatment, specifically targeting the FLT3 protein.
Latest Patents
Linnette Capo holds a patent for "Antibody Drug Conjugates (ADC) That Bind To FLT3 Proteins." This invention describes ADCs that specifically bind to FLT3 proteins and their variants. The distinct expression pattern of FLT3 in normal adult tissues, along with its aberrant expression in various cancers, makes these ADCs a promising therapeutic option for cancer treatment.
Career Highlights
Throughout her career, Linnette has made significant contributions to the field of cancer therapeutics. Her research has focused on the development of targeted therapies that can improve treatment outcomes for patients with FLT3-expressing cancers.
Collaborations
Linnette has collaborated with esteemed colleagues, including Nandini Rudra-Ganguly and Christine Lowe, to advance her research and enhance the effectiveness of her inventions.
Conclusion
Linnette Capo's work in developing antibody drug conjugates represents a significant advancement in cancer treatment. Her innovative approach to targeting FLT3 proteins showcases her commitment to improving therapeutic options for patients.